$OPK

3 stories mentioning OPKUpdated 12d ago

Every FINWIRES story that references OPK, newest first.

OPKO Health Q2 Loss Narrows, Revenue Rises; Shares Gain After Hours

OPKO Health (OPK) reported a Q2 loss late Monday of $0.01 per diluted share, narrowing from the loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.08.Revenue in the three months ended June 30 rose to $163.5 million from $156.8 million a year earlier.Analysts expected $131.2 million.OPKO expects Q3 revenue of $131 million to $142 million. Analysts project $134.7 million.The company expects full-year revenue of $560 million to $585 million. Analysts project $536.8 million.OPKO shares rose 18% in after-hours trading.

$OPK

Wire101d ago

Barrington Downgrades OPKO Health to Market Perform From Outperform

OPKO Health (OPK) has an average rating of overweight and mean price target of $3.76 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $1.08, Change: $-0.13, Percent Change: -10.74%

$OPK

Wire108d ago

OPKO Health's ModeX Therapeutics Begins Trial of MDX2003 for B-Cell Lymphoma

OPKO Health's (OPK) ModeX Therapeutics said Wednesday it has dosed patients with MDX2003 for the potential treatment of relapsed or refractory B-cell lymphoma.The trial includes dose-escalation and dose-expansion phases, the company said.Preclinical proof-of-concept data, along with analyses supporting clinical dose selection, were presented at the 2025 American Society of Hematology annual meeting and the ESMO Targeted Anticancer Therapies Congress 2026, the company said.Price: $1.24, Change: $+0.02, Percent Change: +1.64%

$OPK

Track with the FINWIRES app suite

FolioX

Track OPK in your portfolio

WheelAI

Analyze OPK options with the wheel strategy

StockInsider

See market sentiment on OPK